BI Expands Biomanufacturing Capacity in Europe - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

BI Expands Biomanufacturing Capacity in Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology

Boehringer Ingelheim (BI) has announced in a press release the expansion of its biopharmaceutical manufacturing capabilities at its plants in Biberach, Germany and in Vienna, Austria.

The expansion will include cell-culture and microbial-fermentation capacity and support cell-line and process-development services for BI’s contract manufacturing business. BI has invested approximately EUR 17 million ($26.8 million) to expand cGMP cell banking, process science, cell-line development, and quality laboratories at the two sites.

BI expects to use the expanded resources for services that include monoclonal antibody development, product development using BI’s proprietary high-expression systems, and proprietary plasmid DNA platform. In addition, the facilities will support collaborations with Pfenex on Pseudomonas fluorescens bacterial expression technology and with VTU Technology on Pichia pastoris yeast expression technology.

In the company release, Dr. Dorothee Ambrosius, senior vice-president of Biopharmaceuticals Global Process Science, says, “This is another milestone within our contract manufacturing strategy securing technology leadership and towards increased flexibility and customer orientation.”


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here